Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/08/感谢医生1.png)
“谢谢你们,”Teresa微笑着对医生和护士们说道,“你们的专业和关爱让我感到无比安心。我相信,有了你们,我会战胜这场病魔。”
感谢上海嘉会国际医院的医生护士:
在经历了单采,回输等过程后,Teresa对上海嘉会国际医院的医生和护士们心怀感激。她深深体会到了医护人员的专业和关怀。
在Dr. Vicky Lee及其团队的指导下,整个采集输注过程变得顺利和安心。每一位医生和护士都耐心解释每一个步骤,甚至对回输后会出现的风险都做了有效预防和评估,时刻关注她的身体状况和情绪变化,给予她无微不至的照顾和安慰。并且在心理上给予了莫大的支持。医生和护士的温暖话语和坚定目光,让Teresa在不安时找到了力量。
正是这些医护人员的专业和爱心,让Teresa在对抗病魔的路上充满了信心和希望。她由衷地感谢嘉会医院的全体医护人员,是他们的付出和关怀,让她看到了康复的希望。
我们将持续关注患者的治疗后续,并跟进报道。
#CART #CARTTherapy #Hopeforpatients #FUCASO #Equecel #MultipleMyeloma #jihuiHospital #Shanghai #ChineseCart #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART #cancerfight #cancersurvivor #Jiahuihospital
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/07/副作用Thai1.jpg)
แสงแห่งความหวังใหม่: การเดินทางเพื่อการรักษาข้ามพรมแดนของผู้ป่วยชาวไทย
**แสงแห่งความหวังใหม่: การเดินทางเพื่อการรักษาข้ามพรมแดนของผู้ป่วยชาวไทย**
ที่แผนกโลหิตวิทยา โรงพยาบาลตงจี้เซี่ยงไฮ้ ผู้อำนวยการหลี่ผิง แพทย์ผู้รับผิดชอบการรักษาคุณ P ผู้ป่วยชาวไทยสูงอายุ ได้ให้รายละเอียดเกี่ยวกับภาวะมะเร็งเม็ดเลือดขาวชนิดมัลติเพิลมัยอิโลมาและประวัติการรักษาของเธอ สถานการณ์ของคุณ P มีความผันผวนอย่างมาก เนื่องจากเธอได้รับการรักษาหลายครั้งในประเทศไทย แต่โรคกลับมาเป็นซ้ำอีก ในที่สุดเธอได้เลือกและเชื่อมั่นในการรักษาด้วย CAR-T ในประเทศจีน ด้วยความหวังสุดท้าย
ผู้อำนวยการหลี่กล่าวด้วยความซาบซึ้งว่า “คุณ P เป็นนักสู้ที่กล้าหาญ และความกล้าหาญของเธอทำให้ฉันรู้สึกซาบซึ้ง แม้ว่าการรักษาด้วย CAR-T จะมีผลข้างเคียงอยู่บ้าง แต่เรามั่นใจว่าด้วยการจัดการอย่างมีวิทยาศาสตร์และประสบการณ์ที่กว้างขวางของทีมของเรา เราสามารถให้การดูแลและการป้องกันที่ดีที่สุดแก่เธอได้” เธอย้ำว่า การใช้ยาที่มี CAR-T มนุษย์เต็มตัวอย่าง FUCASO ซึ่งมีภูมิคุ้มกันต่ำ ทำให้ความเสี่ยงของผลข้างเคียงลดลงอย่างมาก มอบความหวังในการหายขาดให้กับผู้ป่วยมากขึ้น
ผู้อำนวยการหลี่และทีมของเธอยังคงยืนหยัดอยู่ในแนวหน้าของการรักษา โดยใช้ประสบการณ์และความเชี่ยวชาญที่กว้างขวางเพื่อให้บริการทางการแพทย์ที่มีคุณภาพสูงสุดแก่ผู้ป่วยทุกคน พวกเขาไม่ได้เพียงแค่รักษาโรค แต่ยังรักษาความหวังและความฝันของทุกครอบครัว ในการต่อสู้กับโรคนี้ พวกเขายืนหยัดร่วมกับผู้ป่วย ทำงานร่วมกันเพื่อมุ่งสู่อนาคตที่สดใส
ให้เราร่วมกันติดตามการเดินทางสู่การฟื้นคืนชีพของเธอที่โรงพยาบาลตงจี้ต่อไป
#การรักษาCAR_T #ผู้ป่วยชาวไทย #โรงพยาบาลตงจี้เซี่ยงไฮ้ #มัลติเพิลมัยอิโลมา #กลุ่มอาการการปลดปล่อยไซโตไคน์ #การรักษามะเร็ง #นวัตกรรมการแพทย์ #การแพทย์ข้ามพรมแดน #HopeReborn #CARTherapy #TongjiHospital #Shanghai #FUCASO #Equecel #MultipleMyeloma #PatientJourney #MedicalBreakthrough #CrossBorderTreatment #CancerSurvivor
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/07/副作用eng1.png)
Expert Perspective: Side Effects and Management of CAR-T Therapy for a Thai Patient
**Expert Perspective: Side Effects and Management of CAR-T Therapy for a Thai Patient**
At the Hematology Department of Shanghai Tongji Hospital, Dr. Li Ping, the chief physician for the elderly Thai patient Ms. P, provided a detailed overview of the patient’s multiple myeloma condition and treatment journey. After experiencing multiple treatments and relapses in Thailand, the patient ultimately chose and trusted CAR-T therapy in China. Dr. Li highlighted that the most common side effect is cytokine release syndrome (CRS), which manifests as fever, hypotension, and difficulty breathing. While most CRS cases are mild to moderate, severe CRS can be life-threatening. She also emphasized that through scientific management, the team’s extensive experience, and the low immunogenicity of the fully human CAR-T product FUCASO, the side effects of CAR-T therapy can be effectively controlled, offering the patient hope for a cure.
We will continue to follow up on this patient’s treatment progress and provide updates.
#CARTherapy #MultipleMyeloma #FUCASO #Equecel #TongjiHospital #Shanghai #MedicalInnovation #CancerTreatment #Hematology #PatientJourney #Immunotherapy
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/06/法语封面.jpg)
Thérapie révolutionnaire apporte un nouvel espoir : le patient suisse Thomas commence le traitement CAR-T à l’hôpital Tongji de Wuhan
**Thérapie révolutionnaire apporte un nouvel espoir : le patient suisse Thomas commence le traitement CAR-T à l’hôpital Tongji de Wuhan**
L’équipe du professeur Li Chunrui de l’hôpital Tongji de Wuhan a mené avec succès un cas de thérapie immunitaire à cellules T à récepteur antigénique chimérique (CAR-T) pour un patient atteint de myélome multiple récurrent et réfractaire, offrant une nouvelle vie au patient suisse Thomas.
Thomas, un patient suisse de 54 ans, lutte contre le myélome multiple depuis près de dix ans. Diagnostiqué pour la première fois en 2016, il a enduré de sévères douleurs osseuses et a subi plusieurs cycles de chimiothérapie systémique et de traitement par anticorps monoclonaux. Bien que son état ait été temporairement contrôlé, les rechutes répétées, dont la plus récente en 2022, ont rendu le traitement de plus en plus difficile.
Cependant, le développement mondial de la thérapie CAR-T a ravivé l’espoir. L’introduction du FUCASO (Eque-cel), le premier produit CAR-T entièrement humain en Chine continentale, a apporté une nouvelle lumière à Thomas. Ce traitement révolutionnaire présente non seulement une faible immunogénicité, mais offre également une efficacité prolongée, permettant aux patients de retrouver une qualité de vie élevée.
Thomas a finalement choisi de recevoir la thérapie CAR-T de pointe à l’hôpital Tongji, cherchant une percée fondamentale dans son traitement. La procédure d’aphérèse a été réalisée par l’équipe hématologique de premier plan de l’hôpital, qui possède une expertise de niveau international et met un accent particulier sur les besoins spécifiques des patients et la sécurité du traitement. Le médecin traitant a expliqué en détail le processus d’aphérèse lors d’une interview, déclarant : “Nous avons précisément collecté des cellules T du corps de Thomas, puis modifié ces cellules dans un environnement contrôlé pour cibler spécifiquement les cellules cancéreuses du myélome multiple. L’utilisation de FUCASO a grandement amélioré la spécificité et le taux de succès du traitement.”
Thomas a exprimé une reconnaissance et une appréciation élevées pour le professionnalisme de l’équipe hospitalière et la transparence du processus de traitement. L’hôpital Tongji a mis à profit sa technologie et ses équipements avancés pour offrir à Thomas une expérience d’aphérèse fluide et efficace, assurant une collecte de cellules T de haute qualité et ouvrant la voie au traitement ultérieur.
Thomas est maintenant rempli de confiance et d’anticipation, attendant avec impatience la nouvelle vie que promet la thérapie CAR-T. Ce nouveau départ marque une étape significative dans son parcours de traitement, injectant un nouvel espoir dans son chemin vers la guérison.
Nous continuerons à suivre le traitement ultérieur du patient et à en rendre compte.
#CART #MyelomeMultiple #FUCASOJourney #Equecel #HopitalTongji #SurvivantDuCancer #CancerDuSang #Immunotherapie #CARTEntierementHumain #TraitementDuCancer
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/03/480P-上海同济泰国患者医生吹一波CAR-T优势2-封面.jpg)
Expert Perspective: Options for CAR-T Therapy in Thai Patients
🌈Expert Perspective: Options for CAR-T Therapy in Thai Patients🌈
🌺In the Hematology Department of Tongji Hospital in Shanghai, Director Li Ping provided a detailed overview of the condition and treatment journey of Ms. P, a middle-aged Thai patient with multiple myeloma. After undergoing multiple treatments and autologous hematopoietic stem cell transplants in Thailand, the patient experienced relapses, ultimately opting for CAR-T therapy in China. Director Li Ping explained that CAR-T therapy represents a significant breakthrough in the field of hematologic malignancies, offering remarkable efficacy for patients with multiple refractory recurrences. The fully humanized CAR-T therapy drug, FUCASO (Eque-cel), known for its low immunogenicity and long-term efficacy, has brought hope of cure to patients. Tongji Hospital’s rich experience and comprehensive management in CAR-T therapy ensure the safety and effectiveness of treatment, providing high-quality medical services to international patients.
🌼We will continue to follow up on the patient’s treatment progress and provide further updates.
#CARTTherapy #MultipleMyeloma #FUCASO #Equecel #TongjiHospital #Shanghai #MedicalInnovation #CancerTreatment #Hematology #PatientJourney #Immunotherapy #patientstory
The latest research findings of BCMA CAR-T therapy for multiple myeloma in 2023 | Equecabtagene Autoleucel (FUCASO)
The latest research findings of BCMA CAR-T therapy for multiple myeloma in 2023 | Equecabtagene Autoleucel (FUCASO®)
![](https://www.medtourcn.com/wp-content/uploads/2023/12/12181.png)
IASO Bio and Innovent presented their latest research findings on the Equecabtagene Autoleucel injection (brand name: FUCASO®) for multiple myeloma at the 2023 American Society of Hematology (ASH) Annual Meeting. This study was primarily based on a post-hoc analysis of the FUMANBA-1 study, an Ib/II phase research assessing the efficacy and safety of this therapy in treating patients with relapsed and refractory multiple myeloma (RRMM).
As of December 31, 2022, with a median follow-up of 18.07 months, deep and sustained responses were observed in 103 evaluable patients. Among these patients, the overall response rate (ORR) was 96.1%, and the stringent complete response/complete response (sCR/CR) rate was 77.7%. Among subjects without prior CAR-T therapy, the ORR reached 98.9%, the sCR/CR rate reached 82.4%, and the 12-month progression-free survival (PFS) rate was 85.5%.
Minimal residual disease (MRD) negativity rate is 94.2% in the total evaluable patients, and all patients who achieved CR or above were MRD negative. The median time to achieve MRD negativity was 15 days, with 80.8% of patients remaining MRD negative at 12 months post infusion.
In addition, Equecabtagene Autoleucel could persist in the body for an extended period of time the median duration was 307.5 days. 12 months after infusion, 50% of patients had a vector copy number (VCN) above the lower limit of detection; and 24 months after infusion, VCN could still be detected in 40% of the patients.
The research findings indicate a strong correlation between sustained MRD negativity and patient progression-free survival (PFS), along with the continuous presence of Equecabtagene Autoleucel in the body, which correlates positively with sustained MRD negativity.
The Equecabtagene Autoleucel injection may improve the long-term survival prospects of RRMM patients, offering enduring deep remission and holding significant importance for the sustained maintenance of MRD negativity in patients.
![](https://www.medtourcn.com/wp-content/uploads/2023/12/shutterstock_1371667121.webp)
About Multiple Myeloma (MM)
Multiple Myeloma is a deadly blood cancer that often infiltrates the bone marrow causing anemia, kidney failure, immune problems, and bone fractures. For multiple myeloma patients, common first-line drug treatments include proteasome inhibitors, immunomodulatory drugs, and alkylating agents. While treatment may result in remission, most patients will inevitably enter the relapsed or refractory stage as there’s currently no cure. As a result, there is a significant unmet need for patients with relapsed/refractory multiple myeloma. In the United States, MM accounts for nearly 2% of all cancer cases, and more than 2% of cancer-related deaths.
According to Frost & Sullivan, the number of new MM cases in the United States rose from 30,300 in 2016 to 32,300 in 2020 and is expected to increase to 37,800 by 2025. Additionally, the total number of patients diagnosed with MM increased from 132,200 in 2016 to 144,900 in 2020 and is expected to rise to 162,300 by 2025. In China, the number of new MM cases rose from 18,900 in 2016 to 21,100 in 2020 and is expected to increase to 24,500 by 2025. The total number of patients diagnosed with MM in China increased from 69,800 in 2016 to 113,800 in 2020 and is expected to rise to 182,200 by 2025.
![](https://www.medtourcn.com/wp-content/uploads/2023/12/12184.jpg)
About Equecabtagene Autoleucel
Equecabtagene Autoleucel is an innovative fully-human anti-BCMA CAR-T cell therapy that uses lentivirus as a gene vector to transfect autologous T cells. The CAR comprises a fully-human scFv, CD8a hinge and transmembrane, as well as 4-1BB-mediated co-stimulation and CD3ζ activation domains. Through rigorous screening and comprehensive in vivo and in vitro evaluation, Equecabtagene Autoleucel has been proven to possess potent and rapid anti-myeloma activity, along with outstanding safety, efficacy, and persistence results.
Equecabtagene Autoleucel has received acceptance for New Drug Application (NDA) from China’s National Medical Products Administration (NMPA) for the treatment of RRMM and has obtained IND approval from the U.S. FDA. Additionally, the company was granted Breakthrough Therapy Designation (BTD) by the NMPA in February 2021, Orphan Drug Designation (ODD) in February 2022, and Regenerative Medicine Advanced Therapy (RMAT) and Fast Track (FT) Designations from the FDA in February 2023. Besides multiple myeloma, NMPA has accepted its IND application for the new extended indication of Neuromyelitis Optica Spectrum Disorder (NMOSD). Innovent and IASO Bio are collaboratively developing Equecabtagene Autoleucel for the treatment of RRMM in mainland China.
![](https://www.medtourcn.com/wp-content/uploads/2023/12/12182.jpg)
About IASO Biotechnology
IASO Bio is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases. Leveraging its proprietary fully human antibody discovery platform (IMARS), high-throughput chimeric antigen receptor T-cell (CAR-T) drug screening platform, and proprietary manufacturing processes, IASO Bio is developing a robust clinical-stage pipeline of multiple autologous and allogeneic CAR-T and biologics product candidates. This pipeline comprises a diversified portfolio of over 10 novel products, including IASO’s flagship asset, Equecabtagene Autoleucel (CT103A), a fully human BCMA CAR-T injection.
In addition to Equecabtagene Autoleucel, the company’s pipeline includes the fully developed in-house human CD19/CD22 dual-targeted CAR-T cell therapy, which has received two IND clearances for treating relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r B-NHL) and relapsed/refractory acute B-lymphoblastic leukemia (r/r B-ALL). CD19/CD22 is currently in Phase I clinical trials for r/r B-NHL. It was also granted ODD by the FDA in October 2021. In the approximately 20 patients dosed to date in the investigator-initiated trial, there were no immune effector cell-associated neurotoxicity syndrome (ICANS) observed in any patient, and the rate of grade 3 cytokine release syndrome (CRS) was less than 5%, with the remainder of patients experiencing no CRS or less than grade 3.
Leveraging its strong management team, innovative product pipeline, integrated manufacturing, and clinical capabilities, IASO aims to deliver transformative, curable, and affordable therapies that fulfill unmet medical needs to patients in China and around the world.